Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

John Higgons Biography and Net Worth

Director of Jounce Therapeutics

J. Duncan Higgons has served as a director on our board of directors since November 2015. Mr. Higgons recently served as chief operating officer of Agios Therapeutics, Inc., or Agios, from 2009 to 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Mr. Higgons serves on the boards of PsiOxus Therapeutics, Rheos Medicines and Auron Therapeutics. Mr. Higgons holds a B.Sc. in Mathematics from King’s College University of London and an M.Sc. in Economics from London Business School.

What is John Duncan Higgons' net worth?: The estimated net worth of John Duncan Higgons is at least $18,260.44 as of April 15th, 2021. Mr. Higgons owns 9,713 shares of Jounce Therapeutics stock worth more than $18,260 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Higgons may own. Learn More about John Duncan Higgons' net worth.
How do I contact John Duncan Higgons?: The corporate mailing address for Mr. Higgons and other Jounce Therapeutics executives is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Jounce Therapeutics can also be reached via phone at (857) 259-3840 and via email at [email protected]. Learn More on John Duncan Higgons' contact information.
Has John Duncan Higgons been buying or selling shares of Jounce Therapeutics?: John Duncan Higgons has not been actively trading shares of Jounce Therapeutics during the last quarter. Most recently, John Duncan Higgons sold 200 shares of the business's stock in a transaction on Thursday, April 15th. The shares were sold at an average price of $10.00, for a transaction totalling $2,000.00. Following the completion of the sale, the director now directly owns 9,713 shares of the company's stock, valued at $97,130. Learn More on John Duncan Higgons' trading history.
Who are Jounce Therapeutics' active insiders?: Jounce Therapeutics' insider roster includes Kimberlee Drapkin (CFO), John Higgons (Director), Richard Murray (CEO), and Elizabeth Trehu (Insider). Learn More on Jounce Therapeutics' active insiders.

John Duncan Higgons Insider Trading History at Jounce Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2021	Sell	200	$10.00	$2,000.00	9,713
3/15/2021	Sell	200	$12.80	$2,560.00	9,913
2/16/2021	Sell	200	$11.78	$2,356.00	10,113
1/21/2021	Sell	1,700	$11.90	$20,230.00	10,513
1/6/2020	Sell	1,500	$8.11	$12,165.00
2/1/2017	Buy	6,700	$16.00	$107,200.00	27,025

John Duncan Higgons Buying and Selling Activity at Jounce Therapeutics

Jounce Therapeutics Company Overview

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Today's Range

Now: $1.88

$1.88

$1.93

50 Day Range

MA: $1.89

$1.84

$1.94

2 Week Range

Now: $1.88

$0.58

$5.87

Volume

11,600,600 shs

Average Volume

2,457,142 shs

Market Capitalization

$98.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75